Second-generation 4,5,6,7-tetrahydrobenzo[ d ]thiazoles as novel DNA gyrase inhibitors

LAMUT, ANDRA?; SKOK, ?IGA; BARAN?OKOVÁ, MICHAELA; GUTIERREZ, LUCAS J; CRUZ, CRISTINA D; TAMMELA, PÄIVI; DRASKOVITS, GÁBOR; SZILI, PETRA ÉVA; NYERGES, ÁKOS; PÁL, CSABA; MOLEK, PETER; BRATKOVI?, TOMA?; ILA?, JANEZ; ZIDAR, NACE; ZEGA, ANAMARIJA; ENRIZ, RICARDO D; KIKELJ, DANIJEL; TOMA?I?, TIHOMIR

Future Medicinal Chemistry

Future Medicine Ltd.

Año: 2020 vol. 12 p. 277 - 297

1756-8919

Aim: DNA gyrase and topoisomerase IV are essential bacterial enzymes, and in the fight against bacterial resistance, they are important targets for the development of novel antibacterial drugs. Results: Building from our first generation of 4,5,6,7-tetrahydrobenzo[d]thiazole-based DNA gyrase inhibitors, we designed and prepared an optimized series of analogs that show improved inhibition of DNA gyrase and topoisomerase IV from Staphylococcus aureus and Escherichia coli, with IC50 values in the nanomolar range. Importantly, these inhibitors also show improved antibacterial activity against Gram-positive strains. Conclusion: The most promising inhibitor, 29, is active against Enterococcus faecalis, Enterococcus faecium and S. aureus wild-type and resistant strains, with minimum inhibitory concentrations between 4 and 8 μg/ml, which represents good starting point for development of novel antibacterials.